- Global Pharma News & Resources

Armas and Shilpa Enter into a Sales and Distribution Agreement to Bring High quality oncology products to U.S. Market

Armas and Shilpa Enter into a Sales and Distribution Agreement to Bring High quality oncology products to U.S. Market Distribution Partnership Agreement

PR Newswire

MANALAPAN, N.J. and KARNATAKA, India, Oct. 8, 2018

MANALAPAN, N.J. and KARNATAKA, India, Oct. 8, 2018 /PRNewswire-PRWeb/ -- Armas Pharmaceuticals Inc. (Armas), a NJ based pharmaceutical marketing & distribution corporation, and Shilpa Medicare Limited (Shilpa), an India based pharmaceutical company, have announced today, a distribution partnership agreement. This agreement will encompass various generic oncology injectables and orals within the U.S. market. The first product, an oncology injectable, to be introduced in late October 2018, has an approximate market size of $116 million annually. Armas expects to launch additional oncology products through the 1st quarter of 2019, with a market size totaling more than $430 million annually.

"We are extremely pleased to have an opportunity to partner with Shilpa Medicare Limited, to provide to the US market quality oncology products. Our highly skilled team also looks forward to identifying products for development, utilizing alternative dosage forms, and delivery methods to improve the patient experience.", says John Niemi, President & CEO of Armas.

"We are very excited about this partnership. The combination of Armas' deep customer experience and Shilpa's vertical integration, high quality development and manufacturing capabilities are well suited to launch our portfolio of products approved and under FDA review while providing affordable medicines to patients.", says Adam Levitt, CEO of Shilpa North America.

About Armas Pharmaceuticals, Inc.
Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information, please visit

About Shilpa Medicare Limited
Shilpa Medicare Limited has its formulation manufacturing facility at Pharma SEZ, Jadcherla, Telangana State, India. It has a state of art manufacturing facility with capability of manufacturing various dosage forms like tablets, capsules & injections according to global regulatory standards. The facility has GMP clearance from Global regulatory authorities viz. US FDA, EU GMP, Brazil-ANVISA, DIGEMID-Peru, WHO GMP etc. The management of the facility is committed to continued compliance with Global GMP requirements. Shilpa Medicare Limited has filed registration dossiers with US FDA, EU Authorities, Latam, GCC, CIS, African countries. The firm also engaged in contract manufacturing. The facility has started commercial supply of the products to different regions of the world – USA, Europe, ROW markets. For more information, please visit


SOURCE Armas Pharmaceuticals

Editor Details

Last Updated: 08-Oct-2018